A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Lumiracoxib
Tandutinib
The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Vemurafenib.
Lumiracoxib
Methsuximide
The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Vemurafenib.
Lumiracoxib
Ezogabine
The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Vemurafenib.
Lumiracoxib
Farnesyl thiopyrophosphate
The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Vemurafenib.
Lumiracoxib
Fleroxacin
The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Vemurafenib.
Lumiracoxib
Vorinostat
The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Vemurafenib.
Lumiracoxib
Pheniramine
The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Vemurafenib.
Lumiracoxib
Solifenacin
The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Vemurafenib.
Lumiracoxib
Ajmaline
The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Vemurafenib.
Lumiracoxib
Methotrimeprazine
The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Vemurafenib.
Lumiracoxib
Cycloguanil
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Cycloguanil.
Lumiracoxib
Tetrandrine
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Tetrandrine.
Lumiracoxib
Piperaquine
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Piperaquine.
Lumiracoxib
Artemotil
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Artemotil.
Lumiracoxib
Artemisinin
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Artemisinin.
Lumiracoxib
Pyronaridine
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pyronaridine.
Lumiracoxib
Mizoribine
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Mizoribine.
Lumiracoxib
Chlorproguanil
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Chlorproguanil.
Lumiracoxib
Artefenomel
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Artefenomel.
Lumiracoxib
Artenimol
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Artenimol.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3